Kratom Is Legal in Most Countries but Causes Real Physical Dependence

Kratom legal status is a regulatory classification that does not determine addiction risk.

Alcohol is legal in most countries and ranks among the most addictive substances assessed by clinical researchers. Tobacco is legal and causes severe physical dependence. Kratom follows the same principle. A substance can be uncontrolled by law while still triggering the biological processes that lead to dependence, tolerance, and withdrawal, which is why kratom belongs in the same opioid dependence discussion as any scheduled drug. Whether kratom causes addiction is decided by neuroscience, not legislation. Legal access affects where people can buy kratom and at what dose, but it does not change how mitragynine interacts with the central nervous system.

People searching for kratom's legal status often do so because they want reassurance that daily use is harmless. The legal status question and the safety question are not the same question. This page addresses the one that matters clinically.

Kratom's addiction potential is explained by its active alkaloid, mitragynine, which binds to mu-opioid receptors in the brain and produces analgesic, sedating, and euphoric effects at higher doses.

At lower doses, mitragynine produces stimulant-like effects, which is one reason people begin using kratom as a productivity supplement or pain management tool. At higher doses and with repeated use, the opioid receptor binding drives tolerance, so the brain requires increasingly larger amounts to produce the same effect. That tolerance is the first sign that dependence is developing. Because that mechanism is opioid-class, the medical detox protocols built for opioid withdrawal apply directly to kratom. It is the same biological process that occurs with codeine, morphine, and fentanyl. The specific alkaloid differs; the receptor mechanism does not.

The receptor pharmacology is not in dispute in the research literature. It is confirmed by work published by the National Institute on Drug Abuse, and 7-hydroxymitragynine, a secondary compound in kratom, also acts on opioid receptors. Pharmacological research identifies it as a partial mu-opioid receptor agonist with greater efficacy than mitragynine, in some studies exceeding the potency of morphine, according to a 2025 review in Pharmaceutical Biology. Both compounds are present in standard kratom products sold in health food stores and online retailers across jurisdictions where kratom remains uncontrolled.

Kratom dependence develops through repeated activation of opioid receptors, producing the same neuroadaptation seen in prescription opioid use, where the brain's own reward and pain-regulation systems downregulate in response to consistent external stimulation.

A person who begins taking kratom for pain relief or anxiety management will find that their original dose no longer produces the same relief, so they increase the dose. Over time, skipping a dose produces withdrawal symptoms, which confirms that physical dependence has been established. Many people arrive carrying an underlying anxiety or mood disorder that has driven use for years, and Jintara's dual diagnosis treatment addresses both the dependence and the condition beneath it. By the point most people recognise they cannot stop without medical help, they have been dependent for months or years, often without applying the word addiction to their situation because the substance is legally available.

The progression follows the same pattern documented across opioid use disorder cases. Darren Lockie, who founded Jintara Rehab after fifteen years building addiction treatment centres in Thailand, describes the clinical reality plainly. Jintara treats a significant number of clients with kratom dependence, and the severity of that dependence is not diminished by its legal status.

The most clinically significant consequence of kratom's legal status is psychological, not pharmacological. A person using kratom daily is far less likely to describe themselves as having an addiction than a person using an illegal opioid, even when the clinical picture is identical.

This belief delays the decision to pursue treatment. People rationalise continued escalating use because the substance is sold in shops, available online, and not scheduled under drug laws in their country. Understanding how the treatment program works helps clarify why kratom dependence responds to the same evidence-based approach used for prescription opioid addiction. They compare themselves to people using heroin or prescription opioids and conclude that their situation is categorically different. It often is not. The distinction is legal, not clinical.

This reflects the clinical position Jintara takes. The treatment protocol for kratom dependence mirrors the opioid detox protocol, because the receptor mechanism is the same. Darren Lockie is blunt about what that means for someone who has convinced themselves a legal supplement could not have taken hold.

Kratom withdrawal symptoms are real, physically uncomfortable, and in high-dose long-term users, severe enough to require medical management. Symptoms typically begin within 12 to 24 hours of the last dose, peak between days two and four, and resolve over five to ten days for most users, with some post-acute symptoms persisting for several weeks.

Common withdrawal symptoms include anxiety and restlessness, muscle aches and joint pain, insomnia, irritability, nausea, sweating, hot and cold flushes, and an intense craving to resume use. The profile is similar to opioid withdrawal but typically less severe than heroin or high-dose prescription opioid withdrawal, a pattern documented in peer-reviewed research on kratom withdrawal and opioid-class dependence. Milder than heroin withdrawal does not mean comfortable or manageable without support. For people on high daily kratom doses, the acute phase can be genuinely distressing and medically significant.

Jintara monitors withdrawal severity using the Clinical Opiate Withdrawal Scale, the same assessment tool used for heroin and prescription opioid withdrawal. Those detox protocols were developed by Darren Lockie over fifteen years of treating opioid-class dependence in Thailand, including the kratom client group that now represents a meaningful portion of admissions. Vital signs are checked hourly through the first 48 to 72 hours of acute detox, nursing staff are awake throughout the night, and medication protocols are adjusted based on the withdrawal scores rather than a fixed schedule.

The Diagnostic and Statistical Manual of Mental Disorders, DSM-5, criteria for substance use disorder do not distinguish between legal and illegal substances. A person who meets two or more of the eleven criteria has a substance use disorder, irrespective of the substance's regulatory status.

For people using kratom, the most commonly met criteria include using larger amounts or for longer than intended, persistent desire or unsuccessful efforts to reduce use, significant time spent obtaining or recovering from use, craving, continued use despite social or interpersonal problems, tolerance requiring increased amounts, and withdrawal when stopping. The full cost of a 30-day program covers the medical detox phase, psychiatric assessment, and therapeutic treatment, whether the admitting substance is opioid, alcohol, or kratom. Many people using kratom daily meet four or more criteria before they consider the possibility that their use has become disordered.

Independent authorities describe the same criteria and the same risk. The National Institute of Mental Health provides a full overview of how these criteria apply across substances, and the National Institute on Drug Abuse states that kratom can cause dependence and that people who use it regularly may experience withdrawal when they stop. Legal availability does not exempt kratom from this classification.

Jintara's kratom withdrawal monitoring protocol applies the Clinical Opiate Withdrawal Scale because mitragynine's opioid receptor mechanism produces opioid-class withdrawal. Nursing staff conduct vital sign checks covering heart rate, blood pressure, temperature, and oxygen saturation on an hourly schedule through the first 48 to 72 hours of acute withdrawal.

Behavioural signs including tremors, sweating, anxiety, and restlessness are documented alongside the withdrawal score, and medication protocols are adjusted based on the clinical picture. The first-week admissions schedule includes the psychiatric assessment and the nursing handover that sets the withdrawal monitoring plan. The opioid-class basis for this monitoring is set out in systematic research on kratom's molecular mechanisms and dependence, which is why kratom is handled with the same tools as any opioid. Medical escalation is available if the withdrawal picture changes, and Jintara maintains hospital transfer agreements with Bangkok Hospital Chiang Mai and RAM Hospital, though for kratom this escalation threshold is rarely reached.

A full psychiatric assessment is included on the day of admission. The psychiatrist reviews the kratom use history, any co-occurring mental health conditions, and any existing medications, and this assessment shapes the detox plan. The clinical team matches the withdrawal management approach to what the assessment reveals, and there is no additional charge for this assessment.